巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Nabriva Therapeutics plc

    NBRV
    0.190
    0.000
    1.61%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Nabriva Therapeutics plc - 延遲價格・最後更新於 27/05 12:14
    最高位
    0.200
    最低位
    0.190
    開市價
    --
    前收市價
    0.193
    成交量(千)
    7.72
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    12.01
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    1.500 - 0.180
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Nabriva Therapeutics plc
    證券代碼
    NBRV.US
    所屬板塊
    Biotechnology
    公司業務
    Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
    發行量
    60525366
    公司總部
    25-28 North Wall Quay, IFSC
    公司網址
    https://www.nabriva.com
    公司電郵
    david.garrett@nabriva.com
    公司電話
    +353 16492000
    暫無內容

    關於

    Nabriva Therapeutics plc(NBRV.US)所屬的行業板塊為Biotechnology。
    Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.
    詳細公司背景可參考: https://www.nabriva.com